Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class  OCU500 Inhaled Vaccine Candidate for COVID-19

1. Homepage
2. Finance
3. Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class  OCU500 Inhaled Vaccine Candidate for COVID-19